Solventum Corporation (SOLV) Stock Price & How to Invest

Solventum is a healthcare company that was spun off from 3M in 2024, combining 3M's former Health Care business into a standalone public company. It operates across several healthcare segments: medical surgical products (wound care, advanced dressings, surgical supplies, infection prevention), dental and orthodontic solutions, health information systems (clinical documentation, coding, and revenue-cycle software for hospitals), and purification and filtration (including water and biopharma filtration). The company makes money selling consumable medical products to hospitals and clinics, software and services to health systems, and filtration technology to industrial and life-science customers. As a recent spin-off, Solventum's story centers on standing up independent operations, paying down debt inherited at separation, stabilizing growth, and improving margins. It holds established brands and large installed bases in several niches. Headquartered in Maplewood, Minnesota, it serves customers across hospital, dental, and industrial end markets globally.

As a recent spin-off, Solventum carries meaningful debt taken on at separation and must prove it can grow organically after years inside 3M, where the business reportedly underinvested. Several segments face slow growth and competitive pressure from larger, better-capitalized rivals. The dependence on 3M for certain transition services and the complexity of standing up independent systems add execution risk. Pricing pressure from hospital cost-cutting, exposure to elective-procedure volumes, and any legacy liabilities associated with former 3M products are additional concerns. Portfolio reshaping (divestitures) could be dilutive if executed at unattractive valuations.

13 analysts publish price targets on SOLV, averaging $84.69 against a $87.03 price as of July 2026, or -2.7%. The published targets run from $60.00 to $100.00, a moderate spread, and the ratings split 8 buy, 5 hold, 2 sell. Over the last six months there has been 1 raise and 6 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full SOLV forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Solventum Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Recurring consumable and software revenue. A large share of Solventum's sales come from consumable medical products and recurring software subscriptions for hospitals, which tend to be stickier than one-time equipment sales. The most optimistic published target, $100.00, assumes this works close to its best case.

The case against. As a recent spin-off, Solventum carries meaningful debt taken on at separation and must prove it can grow organically after years inside 3M, where the business reportedly underinvested. The most pessimistic target, $60.00, is roughly what SOLV is worth if this bites instead.

Read the full bull and bear case on SOLV, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Solventum Corporation's investor relations page or your broker.

• Revenue (TTM): ~$8 billion
• Revenue growth: low-single-digit, roughly flat to slightly up
• Operating margin: ~20% on an adjusted basis
• Net debt: elevated, inherited at the 3M separation
• Free cash flow: healthy but partly directed to debt paydown
• Dividend yield: modest, initiated post-spin
• P/E (forward): low relative to medtech peers

Solventum trades at a discount to faster-growing medtech peers, reflecting its slow top-line growth, elevated post-spin debt, and the work still required to prove independent execution. The qualitative profile is a turnaround and self-help story: stabilize growth, reduce leverage, and expand margins. Successful deleveraging and portfolio reshaping are the key swing factors.

Other names that sit close to SOLV: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get SOLV exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so SOLV sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where SOLV fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Solventum (SOLV) is a recently independent, slow-growth healthcare company whose value case rests on cutting stranded costs, paying down post-spin debt, and reshaping its portfolio. In a portfolio it behaves as a defensive, value-tilted medtech turnaround holding, where successful deleveraging and execution are the main swing factors rather than rapid revenue growth.

Whether SOLV is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is SOLV a buy or a sell?, and where the stock could go from here in the SOLV stock forecast.

For income investors, whether SOLV pays a dividend and how the payout looks is covered in does SOLV pay a dividend? And to weigh SOLV against a peer, read the full side-by-side comparisons: SOLV vs MDT and SOLV vs BAX.